Maralixibat decreases the reabsorption of bile acids from the terminal ileum for the treatment of cholestatic pruritus in patients with Alagille syndrome.
- Men With Stage IV Breast Cancer Benefit from Trimodal Therapy
- FDA Approves Ranibizumab Ocular Implant for Patients With Age-Related Macular Degeneration
- CGM Improves Outcomes for Patients Using Only Basal Insulin
- Pharmacies Play Key Role as Center of Immunization Services
- American Oncology Network In-House Specialty Pharmacy Earns Third Accreditation
- Hello world! on